Thermo Fisher Scientific Sponsors Shanghai Conference on Stem Cell Research
News May 14, 2009
Thermo Fisher Scientific Inc. has announced that it is sponsoring the 2009 Shanghai Symposium of Stem Cell Research and Regenerative Medicine at the Shanghai Tong Ji University, May 14-15, in Shanghai.
The two-day event will be attended by members of the stem cell research community from China and abroad. It will feature presentations by technical experts at Thermo Fisher on the latest tools and techniques available for stem cell research, including RNA interference, protein expression, cellular imaging and new cell culture surfaces.
Dr. Craig Smith, vice president of research and development for life science research at Thermo Fisher, will highlight a range of key stem cell research technologies. These include the newest small-interfering RNA products that enable the study of gene function in neural stem cells, the use of proteomic technologies and high-content image analysis techniques as applied to the study of stem cell differentiation, and the identification of genes and proteins involved in stem cell growth and differentiation.
Dr. Cindy Neeley, application scientist for laboratory consumables at Thermo Fisher, will present novel cell culture surfaces that allow non-enzymatic subculture of stem cells for stem cell research and tissue engineering studies.
The event will be followed by a tour of the Thermo Fisher demonstration laboratory located at Building 6, Xin Jin Qiao Road in Shanghai, where a number of key products and technologies from the Thermo Scientific Stem Cell Excellence portfolio will be displayed.
The Shanghai symposium showcases the Thermo Scientific Stem Cell Excellence program, a companywide initiative that brings together nearly 100 essential laboratory products and services, spanning instruments, consumables, reagents, and informatics as well as service and automation, to address the needs of stem cell researchers.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.